Comparison of the CEDIA® and MEIA® assays for the measurement of sirolimus in organ transplant recipients

Colantonio, David; Borden, Kimberlee K.; Clarke, William

doi:10.1016/j.clinbiochem.2007.02.004

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular complications, biliary ducts anastomotic complications, incisional hernias, rejections, graft and patient survival rate were collected for the entire 5‐year period of follow‐up. Blood trough levels of SRL [19], TAC, and CyA, transaminases (AST, ALT, Total Bilirubin, ALP, LDH), serum creatinine, bone marrow function tests (white blood cell count (WBC), platelet count and hematocrit) and lipid profiles (serum cholestertol and triglycerides levels) were analysed at 1 month, 6 months, 12 months and then yearly until 5 years after OLT.…”

Section: Methodsmentioning

confidence: 99%

Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients

Molinari

Berman

Meeberg

et al. 2010

Transplant International

View full text Add to dashboard Cite

Summary The use of sirolimus (SRL) in orthotopic liver transplantation (OLT) has been controversial after experimental data suggested an increased risk of hepatic artery thrombosis (HAT). To assess the safety and efficacy of SRL as de novo immunosuppression in OLT recipients. Outcomes of 252 OLT patients who received SRL were compared with outcomes of 291 OLT recipients who received calcineurin inhibitor in a retrospective study. Primary outcomes of this study were: patient‐ and graft survivals, vascular, biliary, wound complications and rejection rates. Secondary outcomes were: postoperative infection rate, bone marrow and renal function and changes of lipid levels. Patient‐ and graft survivals, rejection and infection rates were similar. In the SRL group, HAT occurred in 1.2%, biliary complications in 19.4%, and incisional hernias in 9.1%. In the control group the incidence of HAT was 5.8% (P = 0.004), biliary complications 18.5% (P = NS) and incisional hernias 7.2% (P = NS). Patients on SRL experienced significantly higher levels of serum triglycerides but fewer acute cellular rejections. Bone marrow and renal functions were similar in both the groups. Our findings would suggest that SRL is safe and effective for very selected OLT recipients. Randomized controlled trials are necessary to confirm our results.

show abstract

Section: Methodsmentioning

confidence: 99%

Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients

Molinari

Berman

Meeberg

et al. 2010

Transplant International

View full text Add to dashboard Cite

show abstract

“…Comparison of sirolimus values obtained by these assays and a specific LC/MS analytical method showed positive bias of an average 0.9 ng/mL with the MEIA assay and a larger positive bias of 2.1 ng/mL with the CEDIA sirolimus assay. 51 Morris et al 52 compared MEIA sirolimus assay with the values obtained by using a specific LC/MS/MS assay and observed a mean bias of 49.2% (range: 22.4% to 128%) in tacrolimus values obtained by the MEIA assay with the corresponding values obtained by the LC/MS/MS assay. Schmidt et al evaluated the new CMIA sirolimus assay for application on the Architect analyzer (Abbott Laboratories) and concluded that the assay only crossreacts with sirolimus metabolite F4 and F5, but hematocrit has no effect on the assay.…”

Section: Issues Of Interferences In Monitoring Of Immunosuppressantsmentioning

confidence: 97%

Impact of Interferences Including Metabolite Crossreactivity on Therapeutic Drug Monitoring Results

Dasgupta¹

2012

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Therapeutic drug monitoring is an integral part of services offered by toxicology laboratories because certain drugs require routine monitoring for dosage adjustment to achieve optimal therapeutic response and avoid adverse drug reactions. Immunoassays are widely used for therapeutic drug monitoring. However, immunoassays suffer from interferences from both exogenous and endogenous compounds including metabolites of the parent drug. Digoxin immunoassays are affected more commonly than any other immunoassays used for therapeutic drug monitoring. Digoxin immunoassays are affected by endogenous digoxin-like immunoreactive substances and exogenous compounds such as various drugs, certain herbal supplements, and Digibind. Carbamazepine is metabolized to carbamazepine 10, 11-epoxide, and the crossreactivity of this metabolite with carbamazepine immunoassay may vary from 0% to 94%. Immunoassays used for measuring concentrations of tricyclic antidepressants are affected by tricyclic antidepressant metabolites and by a number of other drugs. Immunoassays for immunosuppressants are also subjected to significant interferences from metabolites, and liquid chromatography combined with mass spectrometry or tandem mass spectrometry is recommended for therapeutic drug monitoring of immunosuppressants. However, liquid chromatography combined with mass spectrometry may also suffer from interferences, for example, due to ion suppression or from isobaric ions.

show abstract

“…The authors concluded that although the MEIA assay is suitable for therapeutic drug monitoring of sirolimus, the CEDIA assay based on a higher limit of quantitation that falls within the therapeutic range is not suitable for the therapeutic drug monitoring of sirolimus (70) . The limit of detection was 1.1 ng/mL, and the limit of quantitation was found to be 1.5 ng/mL for the MEIA assay.…”

Section: Limitations Of Sirolimus Everolimus and Mycophenolic Acid mentioning

confidence: 99%

Therapeutic Drug Monitoring of Immunosuppressants: Limitations of Immunoassays and the Need for Chromatographic Methods

Dasgupta

2012

Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Comparison of the CEDIA® and MEIA® assays for the measurement of sirolimus in organ transplant recipients

Cited by 6 publications

References 29 publications

Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients

Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients

Impact of Interferences Including Metabolite Crossreactivity on Therapeutic Drug Monitoring Results

Therapeutic Drug Monitoring of Immunosuppressants: Limitations of Immunoassays and the Need for Chromatographic Methods

Contact Info

Product

Resources

About